



ANTIPROTOZOAL DRUG DISCOVERY: A CHALLENGE THAT REMAINS



Editor:
Norma Rivera

Antiprotozoal Drug Discovery: A Challenge That Remains

Edited By

Norma Rivera

Laboratory of Malariology

Department of Microbiology and Parasitology

Faculty of Medicine

UNAM

Mexico

Antiprotozoal Drug Discovery: A Challenge That Remains

Editor: Norma Rivera

ISBN (eBook): 978-1-68108-329-2

ISBN (Print): 978-1-68108-330-8 ©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2016.

Acknowledgments:

Declared None.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.org



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 PROTOZOAL DISEASES: IMPORTANCE AND PROPHYLAXIS	3
<i>Filiberto Malagón and Elba Carrasco</i>	
INTRODUCTION	3
ECONOMIC IMPORTANCE	4
EPIDEMIOLOGICAL IMPORTANCE	8
The Parasite Reservoir of Infection	8
Processes of Parasite Dispersion	9
Ingress of Parasite to Host	10
Mechanisms of Transmission	11
Congenital Transmission	13
Iatrogenic Transmission	15
<i>By Transfusion</i>	15
<i>Transmission by Organ and Tissue Grafts</i>	18
Parasites and Immune-suppression	19
The Movement of Parasites Worldwide	21
PROPHYLAXIS	23
Poverty	26
Poverty as Disease	28
CONFLICT OF INTEREST	30
ACKNOWLEDGEMENTS	30
GLOSSARY	30
REFERENCES	31
CHAPTER 2 DRUGS FOR PARASITIC DISEASES - STRATEGIES TO SOLVE A GLOBAL PROBLEM	41
<i>A. Valeria Pozzoli and Miriam A. Martins Alho</i>	
INTRODUCTION	41
THE CHALLENGE OF PARASITIC DISEASES	44
DISCOVERING PARASITIC DRUGS	47
Drug Design Based on Nature	47
Developments Based on Structural Similarity	48
Redirecting Drugs	49
The Rational Design	51
PERSPECTIVES	52
CONCLUDING REMARKS	58
CONFLICT OF INTEREST	58
ACKNOWLEDGEMENTS	59
GLOSSARY	59
REFERENCES	59
CHAPTER 3 CRUDE EXTRACTS AND ISOLATED COMPOUNDS WITH TRYPANOCIDAL ACTIVITY	66
<i>Paz M. Salazar Schettino, Gloria Rojas, Margarita Cabrera and Martha Bucio</i>	
INTRODUCTION	67
Biology of Chagas' Disease	68

Vectors	70
<i>Trypanosoma cruzi</i> in the Vectors	71
Natural History of the Disease	71
Pathogenesis of Chronic Cardiomyopathy	74
Laboratory Diagnostics	76
Desk Studies	76
Therapeutic Management of the Infection and Disease	77
CONCLUDING REMARKS	82
CONFLICT OF INTEREST	83
ACKNOWLEDGEMENTS	83
GLOSSARY	83
REFERENCES	84
CHAPTER 4 MALARIA, GENERALITIES AND NEW TREATMENTS	92
<i>Luz Eugenia Alcántara-Quintana, Mónica Salas-Rojas and Emmanuelle Alvarado-Alvarez</i>	
MALARIA GENERALITIES	92
<i>Plasmodium</i> Life Cycle	93
NEW TREATMENTS	94
Quinine	95
Chloroquine	97
Artemisinin	98
Primaquine	100
Resistance	100
CONCLUSION	102
CONFLICT OF INTEREST	102
ACKNOWLEDGEMENTS	103
REFERENCES	103
CHAPTER 5 UPDATE ON ADVANCES IN PLANT-BASED ANTIMALARIAL DRUG DISCOVERY 106	
<i>Pius SOFasinu, Ilias Muhammad and Larry AOWalker</i>	
INTRODUCTION	107
Historical Relationship Between Phytochemicals and Antimalarial Drug Discovery	109
Finding Potential Antimalarial Agents from Natural Products	109
<i>a. Influence of Modern High-Throughput Assay Technologies on Drug Discovery Efforts</i>	109
<i>b. Drug Discovery and Development from Natural Products</i>	110
From Quinine to Several Quinolines	113
Atovaquone	116
Artemisinin and the Endoperoxides	116
Cryptolepine and Related Quinolines	119
Strictosamide and its Derivatives from <i>Nauclea Pobequinii</i>	120
Argemone Mexicana and its Chemical Constituents	122
Vernodalin and its Analogs	124
Febrifugine	125
Others	127
CONCLUSION	140
CONFLICT OF INTEREST	140
ACKNOWLEDGEMENTS	140
GLOSSARY	140
REFERENCES	142
CHAPTER 6 METALS AS AN OPTION FOR PROTOZOA TREATMENT	156
<i>Norma Rivera, Marcela Rojas-Lemus, Gumaro Cano-Gutiérrez, Luis FOMontaño and Teresa I. Fortoul</i>	
INTRODUCTION	156

<i>Trypanosome</i> and Metals	159
<i>Leishmania</i> and Metals	162
<i>Plasmodium</i> and Metals	164
Treatments Against Malaria	165
<i>Toxoplasma, Neospora</i> and Metals	170
<i>Entamoeba histolytica</i> and Metals	172
<i>Trichomonas vaginalis</i> and Metals	172
CONCLUSION	173
CONFLICT OF INTEREST	173
ACKNOWLEDGEMENTS	173
GLOSSARY	173
REFERENCES	174
SUBJECT INDEX	180

FOREWORD

All living creatures have to adjust to the cycle of life. All species have a beginning and have an end and during this period, they experience a breakdown of the homeostasis, call disease. Disease in man is associated to pain, anguish and suffering of the sick individual. More than a million years have been expended to search the causes of diseases, their effects in the body, and how to return patients to health. So many treatment procedures have emerged through human history, from natural products and magic healers to synthetic drugs design and physicians. As you can see, the application of curative measures have not frontiers nor limits.

Probably plants have been the principal source of remedies against disease. Actually, the use of plants, is not very practiced in occidental official medicine, instead, drugs are synthetic compounds that were primarily isolated from plants, fungus, algae, or bacteria. Nowadays, pharmacological industries, make big investments to develop new compounds for chronic and degenerative diseases, but it seems that investment on research to develop new drugs for diseases of the poor, is not one of their goals.

This book approaches the different facets of some of the most important diseases produced by protozoan parasites, under the analysis of epidemiological facts, economical and social impact, prevention and control problems. An analysis of the studies on new drugs for protozoan parasitic diseases, their hopes and achievements, is offered. An overview of the use of medical plants to treat specifically Malaria and Chagas disease, is also presented, as well as the experimental results obtained with the application of various metals in the treatment of malaria, leishmaniasis, toxoplasmosis and trichomoniasis.

This book will be of interest to parasitologists, pharmacologists and chemists and those involved or interested in the isolation and synthesis of active compounds against parasites.

Filiberto Malagón

Laboratory of Malariology

Department of Microbiology and Parasitology

Faculty of Medicine

UNAM

Mexico

PREFACE

Protozoan parasites are a worldwide public health problem that challenge the immune system of millions of humans and non-humans animals, resulting in devastating social and economic consequences. Until now, chemotherapy is central to the control of most of the infections caused by these parasites in both medical and veterinary practice. Chemotherapy control, has been mainly compromised by the development of parasite drug resistance, drugs severe side-effects and toxicity, low to medium efficacy, high cost drugs, and the introduction of counterfeit drugs that are a threat to public health with many overwhelming effects for patients; consequently, the search for new antiprotozoandrugs is an urgent need.

The development of new drugs against these parasites, has been largely neglected because they mainly affect people living in extreme poverty with limited or non-marketing possibilities; for these reasons, in some endemic countries, herbal medicine has become an important and sustainable source of control.

This eBook is an effort of researches who work in the field of antiparasitic experimental chemotherapy and medical parasitology and it summarizes the progresses made in the field of chemotherapy and drug research against protozoan diseases. Synthetic and natural treatments to control Chagas disease, malaria, toxoplasmosis and other parasitic diseases, are discussed in order to open the possibility for applying these scientific progress in the field of antiprotozoan chemotherapy.

The editor and the authors would like to thank Bentham Science Publishers for providing the opportunity to bring this knowledge to the scientific community and to the general public.

Norma Rivera

Laboratory of Malariology

Department of Microbiology and Parasitology

Faculty of Medicine

UNAM

Mexico

List of Contributors

- A. Valeria Pozzoli** LabMOR-INTECIN, Departamento de Química de la Facultad de Ingeniería, de la Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
- Elba Carrasco** Laboratory of Malariology, Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, 04510, Mexico
- Emmanuelle Alvarado-Alvarez** Centre for Science and Technology Studies 14, Luis Enrique Erro, National Polytechnic Institute, Michoacana, Venustiano Carranza, AP. 15240, Mexico City, Mexico
- Filiberto Malagón** Laboratory of Malariology, Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, 04510, Mexico
- Gloria Rojas** Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, 04510, México
- Gumaro Cano-Gutierrez** School of Health Sciences, UVM, Campus Sur, Mexico City, Mexico
- Luz Eugenia Alcántara-Quintana** Potosino Institute for Scientific Research, Road to San José Dam 4th 2055. AP. 78216, San Luis Potosí, Mexico
- Larry A. Walker** National Center for Natural Products Research , University of Mississippi, University MS, 38677, USA
Department of BioMolecular Sciences, Research Institute of Pharmaceutical Sciences, University of Mississippi, University MS, 38677, USA
- Luis F. Montañó** Department of Cellular and Tissue Biology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 04510, Mexico
- Margarita Cabrera** Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, 04510, México
- Marcela Rojas-Lemus** Department of Cellular and Tissue Biology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 04510, Mexico
- Martha Bucio** Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, 04510, México
- Miriam A. Martins Alho** LabMOR-INTECIN, Departamento de Química de la Facultad de Ingeniería, de la Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

iv

- Mónica Salas-Rojas** National Medical Center, XXI Century, Mexican Social Security Institute. Doctores 330, Cuauhtémoc, AP. 06725, Mexico City
- Norma Rivera** Laboratory of Malariology, Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 04510, Mexico
- Paz M. Salazar Schettino** Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, 04510, México
- Pius S. Fasinu** National Center for Natural Products Research , University of Mississippi, University MS, 38677, USA
- Teresa I. Fortoul** Department of Cellular and Tissue Biology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, 04510, Mexico

Protozoal Diseases: Importance and Prophylaxis

Filiberto Malagón* and **Elba Carrasco**

Laboratory of Malariology, Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, 04510, Mexico

Abstract: This chapter focuses on the effect that five parasitic diseases, produced by five protozoa, have on human health, namely: malaria, toxoplasmosis, Chagas disease, leishmaniasis and trichomoniasis. Our approach is the following: An analysis of the epidemiological components of these diseases in the context of the parasite's life cycle; an analysis of the modifications in the natural history of these diseases introduced by human activities such as: migration, iatrogenesis and increased human mobility due to technological advances in the transportation of merchandise and persons; an analysis of how immune suppression produced by other living agents and chemotherapy affects these diseases, and their dispersion by tissue grafts; an analysis of the impact that these diseases have on the society, communities and family economies of countries affected by them, as well as what is being done to prevent them. In conclusion we find that research on new drugs is absolutely necessary to alleviate suffering, but given that these diseases are inextricably linked to poverty, we have to think of poverty as a disease, and as such we have an obligation to prevent it and eradicate it, as in the many other diseases and ills that befall mankind.

Keywords: Chagas disease, Chemotherapy, Leishmaniasis, Malaria, New drugs, Parasitic diseases, Poverty, Prophylaxis, Protozoa, Toxoplasmosis, Trichomoniasis.

INTRODUCTION

The simplest forms of life among the eukaryote are the protozoa, just formed by one cell. The first protozoa probably evolved from the fusion of two bacteria 1.45 to 2.5 billion years ago [1]. These primogenital protozoa, diversified, organized,

* **Corresponding author Filiberto Malagón:** Laboratory of Malariology, Department of Microbiology and Parasitology, Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, 04510, Mexico; Tel: 55 56232465; Fax: 55 56232386; E-mail: malagon@unam.mx

and evolved into multicellular creatures from the trilobites to man. When studying protozoan parasites of man, I suggest not to lose the perception that we, humans, descend from those primogenital protozoa. If we think of humans in this fashion, it is not difficult to recognize that when the cells that conform us face a pathogen protozoa they initiate a relation or confrontation eukaryote to eukaryote and if the balance favors the host the infection is eradicated, but if it favors the parasite, the infection is established [2]. However, in this interaction both may come to an understanding, *i.e.* if the parasite doesn't behave as a parasite then the host will tolerate it. This mutual acceptance is possibly the most common.

Of all the protozoa in nature a minuscule number have learned to use humans as substrate, and of all these, only five are discussed in this book because they are of special significance to human health. The five protozoa referred to in this chapter are: *Plasmodium spp.*, *Toxoplasma gondii*, *Trypanosoma cruzi*, *Leishmania spp.* and *Trichomonas vaginalis*. We will systematically discuss each one of these parasites in the following chapters. In this first chapter we will have a general discussion about all five regarding issues which we find of particular relevance to better understand their importance. The reader will find that in some sections the five parasites are addressed together, while in others we will deal with one parasite or disease specifically.

ECONOMIC IMPORTANCE

When we talk about the economic importance of a disease, we normally talk about the burden that the disease creates at a local, national or global level. Most measurements take into account the premature mortality, morbidity, impairment and disability caused by the disease in study. The study of the global burden of diseases has developed a tool to quantify and compare health between populations, using a joint measure of both mortality and disability called disability-adjusted life year or DALY that measures the loss expressed in years of life due to death or disability caused by a disease [3, 4]. There are however other values that can also give us an idea of the burden produced by a disease.

A general rule created by Sachs and Malaney states that where malaria prospers more, human societies will prosper less. There is an unmistakable correlation

between malaria and poverty. A comparison between the gross domestic product (GDP) of malarial and non malarial countries of similar development showed a GDP of US\$1,526 for the malarial countries while in the non malarial countries it was US\$8,268. This represents a five-fold difference between the two, which suggests that malaria exerts a considerable pressure on the economic development of populations. In a study of the rate of economic growth over a period of 25 years (1965-1990), countries with large populations living in areas of high malarial transmission were compared with countries of similar socioeconomic status but with a lower rate of malaria transmission. The results showed that the former countries had an annual per capita growth of 0.4% while for the latter it was 2.3%. [5].

In a study examining the burden of neglected tropical diseases within the framework of the global burden of disease, malaria was listed as the 9th cause of human death at global level, with 39 million DALYs, and held 1st place in the mortality burden among the tropical diseases of the world in the year 2002 [3].

An analysis of malarial deaths in the sub-Saharan region of Africa, made in 2010, showed a mortality between 655,000 and 1.24 million, with an estimated 82.69 million years lost by disability and death (DALYs), and an associated economic cost of 5.8% of the total GDP of the African Sub-Saharan region. Very important improvements have been achieved in the control of malaria in this region, with the use of residual insecticides impregnated in bed-nets and sprayed in houses, in conjunction with the artemisinin-based combination therapy. However, *Anopheles* resistance to the four classes of insecticides used has been documented, including pyrethroids, the only insecticides used to impregnate bed-nets; the resistance of *P. falciparum* to artemisinin has also been documented [6].

Among human infections caused by parasites, toxoplasmosis is one of the more prevalent, affecting 30 to 50% of the human population. Despite the fact that the infection is long-lived, the vast majority of people remain asymptomatic. The lowest prevalence of toxoplasmosis, of about 1% occurs in some countries in the Far East, and the highest rates, above 90% are found in European and South-American countries. A study of ocular toxoplasmosis in 1042 patients in Southern Brazil showed a prevalence 30 times higher than in any other part of the world

Drugs for Parasitic Diseases - Strategies to Solve a Global Problem

A. Valeria Pozzoli and Miriam A. Martins Alho*

LabMOOr-INTECIN, Departamento de Química de la Facultad de Ingeniería de la Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

Abstract: For many years, one of the driving forces for the development of drugs has been, and still is, the pharmaceutical industry, but the need for therapeutic agents regarding unprofitable diseases makes necessary a change in this situation. Parasitic diseases are a good example since the quantity and safety of many drugs currently in use are inadequate, and the development of new agents is insufficient. In the paper herein, we discuss the main methodologies used for the development and discovery of antiparasitics, the new trends and prospects, as well as the first results achieved by supranational programs and consortia created for such purposes.

Keywords: New approaches, New drugs, Parasitic diseases.

INTRODUCTION

Parasitic diseases are a major socioeconomic challenge either affecting humans or animals. They do not only pose a huge health risk, but also limit the proper development of the affected communities, which, in some cases, represent a large part of the population. Apart from the obvious health risks, these infections have a direct impact on the economic development of the population. Humans affected by certain chronic parasitoses typically develop comorbidities which, either directly or indirectly, affect their quality of life, reduce their productive capacity and limit their potential for economic progress. Moreover, parasitic diseases also affect animals that are in direct or indirect contact with humans. The existence

* **Corresponding author Miriam A. Martins Alho:** LabMOOr-INTECIN, Facultad de Ingeniería, Paseo Colón 850, 5.º Piso, CABA, Argentina; Tel/Fax: 54 11 4343 0893 E-mail: miriam.alho@gmail.com

of infected animals, which are, in some cases, a reservoir allowing these diseases to spread, is also a severe economic damage and results in the loss of animals because they are sacrificed in order to prevent the disease from spreading. Perhaps this is the reason why the parasitic diseases of animals have received comparatively more attention than those of humans from pharmaceutical companies [1].

Part of the lack of interest in human parasitic diseases has been a logical consequence of the roles adopted by different actors in the discovery and development of drugs. Remarkably, the pharmaceutical industry has usually been in charge of said developments, and these companies are profit-driven commercial enterprises. The benefits provided by the commercialization of these drugs do not normally compensate for the large investments needed to develop antiparasitic agents, especially because these diseases are restricted to developing countries with little funding for public health. According to Doctors without borders/Médecins Sans Frontières (MSF), the treatment cost for visceral leishmaniasis is US\$450 per patient in their program in India, but this price can climb to US\$2,500 per patient, which is too expensive for most government Ministries of Health [2]. This is one of the reasons why parasitic diseases have historically been considered “orphan diseases”. The scarce attention received depends exclusively on the academy and/or special programs of either international organizations or nonprofit foundations. Even the resources provided by foundations and nonprofit entities are modest compared to those allocated to the study of other diseases, such as HIV. These huge differences derive from the lack of visibility of parasitic diseases, even when they incapacitate millions of people annually. The World Health Organization (WHO) includes some parasitoses, such as Chagas disease, human African trypanosomiasis (HAT, or sleeping sickness) and leishmaniasis, within the Neglected Tropical Diseases (NTDs). According to the WHO, NTDs do not only affect millions of people across 149 countries, deriving in high costs for developing economies, but also have a high mortality rate if they are not treated properly [2].

In a publication of 2013, Jaggi reported that in the last 20 years the Food and Drug Administration (FDA) has approved 1,200 new drugs and only 3 of them are antiparasitics. Furthermore, not only are there few new antiparasitic drugs, but,

considering the time needed for such drugs to reach the market, there is no prospect either for new alternatives to appear in the near future [3]. This lack of new antiparasitic agents means that drugs developed between 1930 and 1970 are still in use. The constant use of these drugs since then has led to resistance phenomena, thereby reducing their effectiveness. However, the international interest in parasitic diseases is growing because the global landscape of infections is changing. There are two main factors driving this change:

- *The increase in the area of influence of parasitic diseases:* The recrudescence of situations generating social, economic, ethnic, religious and/or political tension turns the migrant issue into a problem difficult to solve. There are thousands of people displaced from their usual areas of residence, leaving behind their past in search of better places to live. In these mass movements, other less obvious “immigrants” come along, which should not be neglected. On the other hand, many people in developed countries travel around the globe, both for professional reasons and out of a desire to visit new places, exposing themselves to health risks which are unusual in their places of residence. In a few words, globalization is also a driving force for the spread of parasitic diseases. The truth is that the emergence of new areas affected by parasites (outside their endemic regions) does not only have an impact on developed countries. In some cases, they are the “exporters” of parasitosis. In Argentina, there have been cases of infections with *Diphyllobothrium latum*, a tapeworm of salmonids found in Canada and Japan, which has apparently been introduced during the planting of trouts. Moreover, in the City of Buenos Aires, an increase of parasitosis has also been verified in recent years, previously rare in said area, along with an increasing incidence of infections with *Taenia saginata* and *Taenia solium*, including the development of cases of neurocysticercosis [4].

While this “importation” of pathologies is often limited to affected individuals, if the parasite finds the appropriate proliferation medium, such as poor hygiene, or the appropriate vectors are present, it can quickly become a mass phenomenon. Regardless of the obvious concern for global health, the increase of people affected by parasites makes this issue more interesting for the pharmaceutical industry. As for the availability of vectors, there is a change that is related to the second factor:

Crude Extracts and Isolated Compounds with Trypanocidal Activity

Paz M. Salazar Schettino*, Gloria Rojas, Margarita Cabrera and Martha Bucio

Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, 04510, Mexico

Abstract: Chagas' disease, or American trypanosomiasis, is a potentially mortal disease caused by the protozoan *Trypanosoma cruzi*. It is included in the list of neglected diseases or poverty-linked diseases. An estimate of 5.7 million people in the endemic areas are infected, resulting in 7000 yearly deaths. The disease is distributed in Central and South America, Mexico, and the southern United States. Due to rural-urban migration, the parasite is transmitted by blood transfusion, by vertical transmission from mother to child, or by organ transplantation; on the other side, some cases have been detected in non-endemic zones both in America and in Europe. Chagas' disease is among the 17 neglected diseases; it is a complex zoonosis, involving interaction of vectors species with wild, peridomestic, and domestic mammals, showing several clinical pictures and transmission modes. It poses the highest economic burden among parasitic diseases in Latin America due to its long chronicity. The clinical manifestations and epidemiologic traits of the disease vary from region to region. The current medication against *T. cruzi*, nifurtimox and benznidazole, has adverse effects. Aiming to make new treatment alternatives known, the activity of plant-isolated compounds from Central America, South America, and Mexico is herein discussed, along with their action against different stages of *Trypanosoma cruzi*.

Keywords: Chagas disease, Crude extracts, Medicinal plants, *Trypanosoma cruzi*.

* **Corresponding author Paz M. Salazar Schettino:** Laboratorio de Biología de Parásitos, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, 04510, Mexico; Tel: (52) 5556232381; E-mail: pazmar@unam.mx

INTRODUCTION

Chagas' disease, or American trypanosomiasis, is a potentially mortal disease caused by the protozoan parasite *Trypanosoma cruzi* and transmitted by hematophagous hemipterans of the Reduviidae family. It is included in the list of neglected diseases or poverty-linked diseases. An estimate of 5.7 million people are infected in the endemic areas, which includes the 21 countries in Latin America, resulting in 7000 yearly deaths and over 70 million are at risk for becoming infected. The disease is distributed in Central and South America, Mexico, and the southern United States [1 - 5]. Rural-to-urban migration in Latin America during the 1970s and 1980s changed the epidemiologic patterns of the disease, turning it into an urban infection where the parasite can be transmitted without a vector [3]. Due to an increase in population movements, the number of diagnosed cases increased even in non-endemic countries both in America and in Europe. A 2011 study reported between 68,000 and 122,000 cases in European countries [6]; this increase poses additional risks for parasite transmission by blood transfusion, vertical transmission from mother to child, or organ transplantation [7 - 9]. Currently regarded as a public health issue in several countries of the Americas, the World Health Organization/Pan American Health Organization (WHO/PAHO) place Chagas' disease among the 17 priority neglected diseases [10 - 12].

The disease was discovered in 1909 by Carlos Chagas, in Brazil. The acute form of Chagas' disease was first described in Berenice, a 2-year-old girl who died at age 82 from other causes. Although infected, she did not acquire the disease. Chagas also described the morphology and the life cycle of the parasite in vertebrate hosts and in vectors insects, and made observations on the course of infection in laboratory animals and in cultures. This clinical entity is a complex zoonosis, with recurrent infections involving the interaction of vectors species with wild, peridomestic, and domestic mammals, showing several clinical pictures and transmission modes. It poses the highest economic burden among parasitic diseases in Latin America due to its long chronicity. Since 1909, Carlos Chagas refers to the rural housing conditions as posing risk or promoting vector propagation, and these conditions are still prevalent nowadays [13]. The clinical manifestations and epidemiologic traits of the disease vary from region to region.

Biology of Chagas' Disease

Trypanosoma cruzi is a flagellate protozoan of the phylum Sarcomastigophora, order Kinetoplastida, and family Trypanosomatidae. The parasite goes through three main developmental stages: trypomastigote (bloodborne when it is in the bloodstream of its mammal host, and metacyclic in the feces of vectors), epimastigote in the intestine of the triatomine and in culture media, and amastigote when located inside the cells of the mammal host. The trypomastigote stage shows a 10-20 μm elongated body, vesicular nucleus, slightly granular cytoplasm, and a terminal kinetoplast with diffuse chromatin from which the membrane emerges. Epimastigote is fusiform and can be up to 30- μm long; kinetoplast has a chromatin organized in a compact manner at the anterior portion, near the nucleus; the parasite has a flagellum and an undulating membrane. Amastigote does not exhibit an external flagellum, but nucleus and kinetoplast are visible; the cell, 3-5 μm in diameter, is a multiplication or fission form inside host cells [14 - 17]. Both vectors arthropods and humans play a role in *T. cruzi* life cycle, along with a large number of reservoir mammals, mainly possums, armadillos, squirrels, field mice, rats, donkeys, pigs, dogs, and cats [18].

Vectors insects carry the infective forms (metacyclic trypomastigotes) of *T. cruzi* in feces, which are deposited on the skin during or after feeding; after entering the host through skin or mucosa, the parasite is able to invade a wide variety of cells where it transforms into the amastigote stage, a replicative intracellular form. Eventually, amastigotes will give rise to trypomastigote forms, which disseminate to other cells and can be ingested by the vector. When a triatomine ingests blood from an infected mammal, the parasite enters the bug; epimastigotes develop in the intestine lumen of the insect, multiplying by binary fission, and about 15-30 days later the metacyclic trypomastigote stage, the infective form, is produced and expelled with the feces of triatomines. When a parasite-infected triatomine feeds again on a healthy mammal, its stomach fills to repletion and discharges feces containing metacyclic trypomastigotes (Fig. 1).

Trypanosoma cruzi has a wide array of surface molecules that allow it to make contact with mammal cells and complete the infection process. Membrane molecules start a host-parasite signaling process; among these, lipid rafts in

Malaria, Generalities and New Treatments

Luz Eugenia Alcántara-Quintana^{1,*}, Mónica Salas-Rojas² and Emmanuelle Alvarado-Alvarez³

¹ Potosino Institute for Scientific Research, Road to San José Dam 4th 2055. AP. 78216, San Luis Potosi, Mexico

² National Medical Center, XXI Century, Mexican Social Security Institute. Doctores 330, Cuauhtemoc, AP. 06725, Mexico City, Mexico

³ Centre for Science and Technology Studies 14, Luis Enrique Erro, National Polytechnic Institute, Michoacana, Venustiano Carranza, AP. 15240, Mexico City, Mexico

Abstract: Malaria is still a grave public health problem in tropical areas of the world. The greater genetic diversity of *Plasmodium vivax* at geographic sites with less control over infection reveals the importance of genetic studies of these parasites. *Plasmodium vivax* is the main cause of human malaria in Asia and Latin America but is absent from most of central Africa due to the near fixation of a mutation that inhibits the expression of its receptor, the Duffy antigen, on human erythrocytes. The search for vaccine development remains an issue of global concern.

Keywords: Dufy antigen, Malaria, New Treatments, *Plasmodium vivax*, Quinine, Vaccines.

MALARIA GENERALITIES

Malaria is an acute or chronic tropical disease caused by protozoans of the genus *Plasmodium*. This protozoan occurs in red blood cells. The hosts of *Plasmodium* are humans and other mammals as well as reptiles and birds. Malaria in humans is caused by five species of *Plasmodium*: *Plasmodium falciparum*, occurring mainly

* **Corresponding author Alcántara-Quintana LE:** Molecular Biology, Potosino Institute for Scientific Research, Road to San José Dam 4th 2055. AP. 78216, San Luis Potosi, Mexico; Tel: 52 (444) 834 20 00 ; E-mail: luz.alcantara@ipicyt.edu.mx

in countries with a tropical climate, in particular in Sub-Saharan Africa (south and center of the continent); *Plasmodium vivax*, having the broadest range of occurrence (from the tropical to the moderate zone); *Plasmodium malariae*, occurring sporadically in countries with a subtropical and tropical climate; *Plasmodium ovale*, occurring in the west of Africa, the Philippines, east of Indonesia and in Papua New Guinea; and *Plasmodium knowlesi*, occurring in south-east Asia, Singapore, Malaysia and Thailand. Among the five species, the most dangerous is *Plasmodium falciparum*.

In the malarian transmission approximately 30–40 species of mosquitoes of the genus *Anopheles* fulfill the significant role of vectors. The mosquitoes responsible for spreading the disease breed in various bodies of water; they like puddles and also rice fields. The number of mosquitoes depends on a large extent on the rainfall intensity, temperature and humidity. The most suitable conditions for mosquito development and malaria transmission are the air temperature of 17–33 °C and the mean relative humidity above 60%. Most blood-sucking mosquitoes are crepuscular feeders [1].

***Plasmodium* Life Cycle**

The Life Cycle is almost the same for all the species that infect humans (Fig. 1).

In humans, the parasites grow and multiply first in the liver cells and then in the blood red cells. In the blood, successive broods of parasites grow inside the red cells and destroy them, releasing daughter parasites ("merozoites") that continue the cycle by invading other red cells [2 - 5].

The blood stage parasites are those that cause the symptoms of malaria. When certain forms of blood stage parasites ("gametocytes") are picked up by a female *Anopheles* mosquito during a blood meal, they start another, different cycle of growth and multiplication in the mosquito [2 - 5].

After 10-18 days, the parasites are found (as "sporozoites") in the mosquito's salivary glands. When the *Anopheles* mosquito takes a blood meal on another human, the sporozoites are injected with the mosquito's saliva and start another human infection when they parasitize the liver cells [6 - 9].

Thus the mosquito carries the disease from one human to another (acting as a

Update on Advances in Plant-based Antimalarial Drug Discovery

Pius S. Fasinu^{1,*}, Ilias Muhammad¹ and Larry A. Walker^{1,2}

¹ National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University MS, 38677, USA

² Department of BioMolecular Sciences, University of Mississippi, University MS, 38677, USA

Abstract: Malaria remains one of the major infectious diseases with high morbidity and mortality in developing and under-developed countries of the world. Although readily curable, the development of resistance by the malaria parasite especially *Plasmodium falciparum*, to existing antimalarials necessitates the need for continuous search for new antimalarial drugs. Several approaches have been adopted in this search including those based on natural products, particularly medicinal plants and herbs. As exemplified in the discovery of quinine and artemisinin, there has been intensified effort in the search of safe and efficacious plant-based antimalarial compounds. This search has yielded moderate success. The current chapter highlights the most promising plant-based drug discovery success with particular emphasis on studies that have reached some advanced clinical stages. With many plant-based compounds exerting antimalarial activities through multiple mechanisms, it is expected that further studies will complement current research efforts towards successful antimalarial drug discovery and development.

Keywords: Artemisinin, Chloroquine, Drug discovery, Herbal medicine, Malaria, Natural products, Plant-derived drugs, *Plasmodium falciparum*, Quinine, Reversed pharmacology.

* Corresponding author Pius S Fasinu: National Center for Natural Products Research, University of Mississippi, University MS, 38677, USA; Tel: 1-662-915-1005; Fax: 1-662-915-1006; E-mail: psfasinu@olemiss.edu.

Norma Rivera (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

INTRODUCTION

Malaria has remained a major health challenge in several countries of the world and according to the World Health Organization (WHO) 2014 malaria statistics, 97 countries and territories of the world have ongoing malaria transmission with 3.3 billion people at risk, an estimated 198 million cases and 584000 deaths in 2013, 85% of who are children under 5 years old [1]. Pregnant women are among the group hardest hit by malaria prevalence, and made worse by limited drug choices. *Plasmodium falciparum*, the most virulent malaria parasite, has developed resistance to most of the available antimalarial drugs [2]. The current standard of treatment as recommended by WHO is artemisinin (ART)-based combination therapy (ACT) comprising artemisinin (or its derivative) in combination with another antimalarial usually an arylamino alcohol or 4-aminoquinoline [3]. Increasing reports of malaria resistance to ACTs, occasioned by delayed cure of parasitaemia and fever symptoms in patients in Southeast Asia and Africa, is a current threat which can only be offset, in the long term, by the discovery of new antimalarial drugs [4, 5].

There is a general consensus on what an ideal antimalarial drug should be. Apart from effectiveness against malaria and demonstration of superiority over existing drugs, an acceptable antimalarial drug should exert actions *via* novel mechanisms that will safeguard against parasite resistance. More important, however, is the economic factor. Malaria is prevalent in developing and under-developed countries of the world. The resource limitation implies that effective drugs should be affordable in order to reach the target population and enhance treatment compliance. Several approaches have been adopted in antimalarial drug discovery and development. These include optimization of therapy through existing drugs. This generally involves the combination of unrelated antimalarial drugs to explore multiple mechanisms of action against the parasite as seen in various marketed antimalarial formulations [6]. Another approach is the development of analogs of existing antimalarial drugs with the purpose of improving efficacy and safety. This approach has been successful with, for example, the development of several aminoquinolines based on quinine [7]. And yet another approach is the search for bioactives and lead compounds from natural products.

The historical relevance of plant-derived compounds in antimalarial chemotherapy suggests that, despite the limited success in recent times, successful antimalarial drug discoveries are possible from botanicals. Natural products present an endless source of potential new pharmacophores upon which synthetic analogues and modifications can be based. Several novel compounds are yet undiscovered from plants many of which, like quinine and ART, are not only therapeutically active on their own, but provide new leads into synthetic antimalarial drug discovery. The high perception of safety of natural products by health consumers, often founded on centuries of traditional use, has made natural products more appealing and acceptable as potential sources of therapeutic agents. While this perception seems to favor popular trust in herbal products, it should be noted that phytochemicals are not always free of toxicity and safety data are required before regulatory approval.

In most malaria-endemic communities, there is anecdotal evidence of antimalarial activity for a wide range of ethnobotanical remedies. This provides the basis for initial antimalarial screenings and bioassay-guided isolation and purification in drug discovery [8]. Additionally, there is some commitment to research and preservation of traditionally useful ethnobotanical resources in malaria-endemic countries [8] especially in Africa. Apart from global climate change, which poses a threat to expand malaria towards the areas of high elevation in Africa and South Asia, as well as the resultant climate change due to rapid urbanization and other human activities has been recognized as responsible for increasing the number of valuable traditional plants going into extinction [9]. These factors highlight the urgency and favorable considerations in antimalarial drug discovery focusing on natural products to provide leads.

In this chapter, an update on plant-based antimalarial drug discovery efforts is provided with emphasis on those lead compounds and products that have reached some stages of assessment in humans since after the discovery of quinine. A brief description of the discovery of the prototypical natural product antimalarial drugs quinine and ART is included to provide historical perspective of the relationship between malaria drug discovery and phytochemicals.

Metals as an Option for Protozoa Treatment

Norma Rivera¹, Marcela Rojas-Lemus², Gumaro Cano-Gutierrez³, Luis F. Montaña² and Teresa I. Fortoul^{2,*}

¹ Laboratory of Malariology, Department of Microbiology and Parasitology, School of Medicine, National Autonomous University of Mexico. Mexico City, 04510, Mexico

² Department of Cellular and Tissular Biology, School of Medicine, National Autonomous University of Mexico. Mexico City, 04510, Mexico

³ School of Health Sciences, UVM, Campus Sur, Mexico City, Mexico

Abstract: Protozoa infections are a worldwide health problem that preferentially affects populations in underdeveloped countries. *Plasmodium*, *Leishmania*, *Trypanosoma*, *Toxoplasma*, *Neospora*, *Entamoeba* and *Trichomonas* are some of the most important genres of protozoan parasites that infect and invade cells, tissues and organs. These parasites proliferate, migrate and mutate to evade the chemotherapeutic effects of drugs that were previously effective for their treatment. The use of metals and metals complexes to control and treat these parasites, seems a very prominent alternative. Palladium, platinum, ruthenium, antimonium, gold, iron and vanadium are some of the metals that have been evaluated as antiprotozoal treatments with favorable results. A review of the experimental effects of metal complexes on these parasites follows, along with commentary.

Keywords: Antimonium, Gold, *Leishmania*, Metal treatments, *Plasmodium*, Platinum, Palladium, Ruthenium, *Toxoplasma gondii*, *Trypanosoma*, Vanadium.

INTRODUCTION

There are 38 transition metals included in the periodic table. These metals contents ductility and malleability characteristics, frequently display numerous

* **Corresponding author Teresa I Fortoul:** Department of Cellular and Tissular Biology, School of Medicine, UNAM, Mexico City 04510, Mexico; Tel: +525556232399; Fax: 525556232182; E-mail: fortoul@unam.mx

regular oxidation states, have electrons in more than one group and are capable of conduct electricity and heat. There is a positive charge in the center of these metals that let them bind to other biomolecules of negative charge; by using these main features of the transition metals, the development of new metal-based compounds with favorable therapeutic uses, has been possible. With the discovery of cisplatin in 1965, a new field of research emerged to investigate the therapeutic features of metals [1].

The advantage in using metal based compounds instead of carbon compounds when designing new therapeutic drugs, is the ability of metals to coordinate ligands in a three dimension shape, in order to define molecular targets [2].

Treatment of protozoan experimental infections with metal compounds, are now being recognized. Protozoan parasites infect over a half billion people worldwide and continue to be one of the most significant public health problems causing a global impact. Some important human diseases caused by these pathogens include malaria, leishmaniasis, Chagas disease, toxoplasmosis, amebiasis and trichomoniasis. Most of the current drugs for these illnesses have been used for decades and have many limitations, such as the emergence of drug resistance, severe side-effects and low-to-medium drug efficacy; these drugs have been largely neglected as models for drug development because they are mainly used in countries with limited resources and as a consequence, with scarce marketing possibilities. Currently, there is a demand to develop new drug-based anti-protozoan therapies [3].

According to a report from the WHO, in 2013, malaria caused 584,000 deaths, with African children being the most affected population. Trypanosomiasis (sleeping sickness) has decreased in frequency, and new cases are located in Africa. From 100 to 200 new cases were reported in Chad and South Sudan in 2013. For Chagas disease, approximately 6 to 7 million people are estimated to be infected worldwide, mostly in Latin America; almost 30% of the infected people develop to a chronic phase with cardiac complications, and about 10% of these chronic patients may present digestive or neurological symptoms [4]. In addition, because the affected populations are usually located in underdeveloped countries, new treatments are not a priority for large pharmaceutical laboratories.

Leishmaniasis is distributed worldwide and is an endemic disease in more than 90 countries across almost every continent. For the treatment of leishmaniasis in humans, a selection of therapeutic compounds is offered, but the drugs are toxic and present adverse effects [5].

Worldwide, around 30% of people is infected with *Toxoplasma gondii*. Severe disease and major complications like encephalitis, myocarditis and pneumonitis are described in immunocompromised patients as a consequence of a primary infection or reactivation of a chronic one; also the fetus can be severely damage during gestation with long-term disabling sequelae, stillbirths or fetal death [6]. *Neospora caninum*, the etiologic agent of neosporosis, is an overwhelming apicomplexan parasite with worldwide distribution that causes reproductive loss in cattle and neuromuscular damage in dogs [7]. Human amebiasis caused by *E. histolytica*, is responsible for almost 50,000,000 diarrheal infections and 100,000 deaths per year. This infection is remarkably common in children from developing nations [8]. A very important sexually transmitted disease is caused by *Trichomonas vaginalis*. Trichomoniasis is a very important public health problem because it produces reproductive damage and enables the acquirement and the transmission of HIV [9].

The research of bioactive metal complexes is an opportunity to find new and less expensive treatments for these diseases [10]. This review identifies the history of these parasite infections and recollects the chemotherapy and different metals already in use along with those proposed as possible treatments for the aforementioned protozoa [11].

Table 1. Experimental use of metals against some protozoan parasites.

<i>Parasite</i>	<i>Metal/compound</i>	<i>Reference</i>
<i>Leishmania</i>	Copper	[12]
	Nickel	[13]
	Zink	[14]
	Iridium	[15]
	Palladium	[16]
	Osmium	[17]
	Vanadium	[18]

SUBJECT INDEX

- 6-hydroxy-5-normethylbudmunchiamine
128
- 6-hydroxybudmunchiamine 128
- A**
- Acidic parasite food vacuole 45
- Acrylate 134
- Activity 11, 48, 49, 54, 58, 66, 78, 111,
112, 113, 126, 127, 142, 160, 161,
163, 170
antiplasmodial 127
biological 142
- African trypanosomiasis 160
- Agents 47, 169
first antimalarial 47
potential antimalarial 169
- Albendazole 49
- Alkaloids 113, 119, 120, 128, 140
- Amastigotes 30, 68, 80, 82, 83, 162, 163
- American trypanosomiasis 6, 66, 67, 83,
160
- Amphotericin 25, 45, 50, 57, 163, 169
- Amygdalina 124, 125
- Analog, first generation 116
- Anemia 16
- Anopheles mosquitoes 12
- Anopheline mosquitoes 11, 22
- Antimalarial 20, 25, 26, 47, 52, 55, 94, 99,
100, 106, 107, 108, 109, 110, 111,
113, 114, 115, 117, 119, 120, 122,
123, 125, 126, 127, 140, 141, 166,
168
action 122
activity 108, 117, 119, 122, 125, 126,
141, 168
demonstrated potent 119
high 168
agent 47
first natural 94
chemotherapy 108, 109
compounds ellipticine 120
constituent, active 117
drug development 117
drug discovery 106, 107, 108, 109,
115, 127, 140
drugs 25, 100, 107, 109, 110, 115
basic 26
effective 109, 113, 114, 120
existing 107, 125, 140
first 109
ideal 107
new 106, 107, 117, 166
potential plant-derived 140
synthetic 25, 122
unrelated 107
drugs discovery efforts 140
efficacy 111, 113, 122
potentials 110
principle 113
properties 52, 113
existing 106
promising 119, 122
strong 126
traditional 109
screenings, initial 108
treatment 20
second-line 123
- Antiparasitic(S) 41, 42, 43, 44, 47, 48, 49,
51, 52, 56
activities 48, 52
agents 42, 56
developing new 52
new 43, 49

Norma Rivera (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

- drugs 45, 49
 acridine 49
 new 42
 new 44
Apicomplexan parasites life cycle 31
Apigenin 79
Argemone Mexicana 53, 122, 123
Armed conflicts 165
Artoindonesianin 131
Ascariasis 45, 46
Asteraceae 78, 79, 81, 82, 116
Asymptomatic parasitaemia 141
Atovaquone 45, 101, 109, 115, 116, 141, 167
- B**
- Benznidazole 45, 58, 66, 77, 83
Berghei 138, 168
Biology of Chagas' disease 68
Blood 10, 15, 16, 17, 22, 31, 66, 67, 73, 93
 malarial 16
 banks 15, 17, 73
 meal 10, 93
 serum 31
 stage parasites 93
 transfusion 16, 22, 66, 67
 units 15, 16
Bone marrow 14, 18
Bradyzoites 170, 173
Braziliensis 163
Brucei gambiense 46, 47
- C**
- Caesalpinia crista 135
Candidates 17, 53, 55
Carboplatin 159, 160
Cardiomyopathy, chronic 73, 74
Cardiopathies 76
Carrasco of imported malaria 22
Cause malaria 164
Cell packages 17
Cells 3, 4, 46, 68, 69, 75, 98, 162, 164, 171
 mammal 68, 69
 mammalian 162, 164
Central nervous system (CNS) 20, 45, 46
Cerebral malaria 116
Chagas 3, 6, 7, 8, 11, 12, 14, 23, 24, 26, 31, 42, 45, 58, 66, 67, 68, 71, 72, 73, 74, 77, 82, 83, 84, 157, 160
 carlos 67
 disease 3, 6, 7, 8, 11, 12, 14, 20, 23, 24, 26, 31, 42, 45, 51, 58, 66, 67, 68, 71, 72, 73, 74, 77, 82, 83, 84, 157, 160
 disease, acute 73
 disease, asymptomatic 73
 disease, chronic 20, 51, 74
 disease and leishmaniasis 11
 disease cases 14
 disease parasites 84
 disease transmission 12
Chemical structures for quinine 48, 49
Chemotherapy 3, 19, 24, 77, 158, 160, 165
Chloroquine 25, 26, 45, 48, 49, 97, 98, 100, 101, 102, 106, 109, 115, 141, 166, 167, 169
 substituted 25, 26
 analogues 97
 -resistant *Plasmodium falciparum* infection cases 100
Chronic 7, 26, 75, 76, 77, 92, 157
 disease 7, 26
 phase 75, 76, 77, 157
 tropical disease 92
Cimbopogon citratus 79, 80, 81
Cisplatin 157, 159, 160

- Clindamycin 96, 115, 170
Clotrimazole 161
Communities 28, 29, 108
 malaria-endemic 108
 poor 28, 29
Complexes 52, 160, 161, 162, 169, 172, 174
 nitrosyl 162
Complex zoonosis 66, 67
Compounds 106, 110
 plant-based antimalarial 106
 potential antimalarial 110
CQ-resistant 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139
 FcB1 132, 135
 FcB1-Columbia strains 132
CQ-sensitive 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139
Cruzipain 70, 83
Cryptolepine 119, 120
Cryptolepis sanguinolenta 119, 128
Cucurbitacin 136
Cyclolignan-7-one 132
Cynaropicrin 79
Cystein proteinases (CPs) 83
- D**
- Deaths, malarial 5
Desferrioxamine 171
Dihydroartemisinin 98, 116, 117
Discovering parasitic drugs
47 Discrete typifying units
70
Diseases 3, 4, 5, 6, 8, 9, 11, 13, 15, 19, 21, 23, 24, 25, 27, 28, 29, 30, 31, 41, 42, 44, 50, 53, 58, 66, 67, 71, 72, 74, 76, 77, 83, 84, 93, 106, 141, 158, 159, 160, 162, 163, 164, 165, 170, 173
 endemic 27, 158
 five 8
 infectious 29, 106, 141
 mortal 66, 67
 neuromuscular 170
 orphan 42
 poverty 30
 poverty-linked 66, 67
 protozoan 23, 173
 rheumatological 19
 skin 141
 sylvatic 13
 transmitted 9, 158
 unprofitable 41
Disease transmission 55
Donors 15, 18, 19
 malarious 15
 seropositive 18, 19
Doxycycline 95, 96, 115
Drug discovery 29, 52, 106, 108, 110, 112, 140, 141, 142
 clinical antimalarial 140
 synthetic antimalarial 108
Drug discovery process 111, 112
Drugs 29, 45, 47, 48, 52, 56, 77, 83, 96, 97, 99, 102, 107, 109, 116, 141, 171, 157, 164, 165
 current 102, 141, 157
 designing new therapeutic 157
 effective 29, 45, 107, 109, 164
 existing 107

- first synthetic 165
 - malarial 96, 97, 99
 - new active synthetic 48
 - new antitrypanosomal 77
 - not-for-profit 52
 - oral 56
 - potential 83
 - promising 171
 - rediscovered 47
 - reliable 116
 - Drugs delivery 173
 - Drugs discovery process 111
 - Drugs resistance 101
 - Duffy antigen 92
- E**
- Effects, antimalarial 20
 - Efficacy 55, 56, 77, 112, 113, 117, 125, 162, 163
 - excellent parasiticidal 163
 - Eflornithine 46, 50, 56
 - Elements, scanty parasitic 74
 - Endemic 14, 16, 17, 19, 21, 22, 43, 66, 67
 - areas 16, 66, 67
 - regions 14, 17, 19, 21, 22, 43
 - Endoperoxides 116, 117, 118, 141
 - sesquiterpene 116, 117
 - Entities, active antimalarial 109
 - Epimastigotes 68, 71, 78, 79, 80, 81, 82, 83, 162
 - strain 82
 - Eukaryote 3, 4
 - Eurixenous 8, 9, 30
 - Extracts 53, 113, 119, 121, 122, 124, 125, 127
 - antimalarial 127
 - ethanolic 79, 121
- F**
- Favors malaria 20
 - Febrifugine 125, 126, 141
 - Fexinidazole 56
 - Fibrosis 74
 - Flavonoids 79, 82, 131, 141
- G**
- Giardiasis 46
 - Gold complexes 160, 168, 169
 - Gramineae 79, 80, 81
 - Gross domestic product (GDP) 5
- H**
- Halofuginone 126
 - Helenalin 134
 - Herbal medicine 106, 141
 - Herbal products 108, 110, 111, 112, 140
 - Host 9, 31
 - definitive 9, 10, 23, 31, 67
 - intermediary 9, 10, 31
 - vertebrate 10, 23, 67
 - Host 50, 68, 69, 70, 110, 163, 171, 173
 - cells 50, 68, 69, 70, 110, 163, 171, 173
 - parasite signaling process 68
 - Human 3, 42, 59, 92, 108, 157
 - activities 3, 108
 - African trypanosomiasis 42, 59
 - diseases, important 157
 - malaria 92
 - Hydroxychloroquine 95, 98
- I**
- Immunosuppression 18, 19, 20
 - Imported malaria 22

- Infantum 7, 13, 17, 163
- Infections 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 29, 41, 43, 48, 51, 67, 71, 72, 73, 74, 77, 84, 92, 93, 96, 98, 141, 158, 160, 162, 163, 164, 166, 170
- acute 72, 170
- chloroquine-resistant 96
- chronic parasitic 71
- congenital 13, 15
- gondii 6, 23
- human 5, 23, 24, 93
- malarial 15, 141
- neglected parasitic 8
- post-transplant 18
- primary 73, 158
- resistant 163
- transmitted 8
- Infective 9, 10, 12, 13, 27, 28, 31, 68, 71, 170, 174
- forms 9, 10, 12, 13, 27, 28, 31, 68, 71, 170
- intracellular parasite stages 174
- Ingress of parasite to host 10
- Inhibitors, proton pump 49, 59
- Insecticides 5, 24, 25, 29
- Insects, blood sucking 9, 10, 13
- Intracellular parasitocidal activity 161
- Iodoquinol 46, 48, 49
- Isocentratherin 134
- Istanbul 17, 18
- Ivermectin, antiparasitic drug 50
- K**
- Ketoconazole 57, 161, 163
- Kinetoplast 68
- Kissing bugs 11, 12, 23, 24, 31
- L**
- Labiatae 79, 80
- Lactoferrin 173, 174
- Lapachol 109, 115, 116
- Lapinone 115, 116
- L. donovani* 7, 13, 14, 25, 163, 164
- Left ventricle enlargement 76, 77
- Leishmania* 12, 13, 17, 30, 31, 57, 156, 158, 162, 167, 168
- treatment 169
- parasites 30, 31
- Leishmaniasis 3, 7, 8, 11, 20, 22, 27, 31, 42, 45, 46, 57, 157, 158, 162, 163
- Lesions, parasitic 31
- Life cycle, parasite's 3
- Life cycle of *Trypanosoma cruzi* 69
- Lifelong expenses 7
- Limit malaria transmission 165
- Limit parasite development 171
- Liver stage parasites 110
- Liver transplants 18, 19
- M**
- Macrophages 70, 74, 75, 161, 162, 171
- Malaria 4, 5, 8, 9, 11, 12, 14, 15, 16, 18, 20, 21, 22, 25, 26, 30, 53, 59, 92, 93, 94, 95, 98, 100, 106, 107, 108, 109, 110, 111, 114, 115, 116, 117, 125, 141, 165, 166, 167, 174
- cases 98
- cause 141
- complications in organ transplants 18
- drug discovery 108
- endemic countries 22
- endemic lands 21
- endemic zones 21
- fever 109
- generalities 92
- infections 16, 20, 21, 22, 166

- asymptomatic 14
 - preexisting 16
 - preventing 116
 - knowlesi 8
 - parasites 116
 - live 110
 - parasite resistance 26
 - parasites 9, 11, 12, 16, 30, 94, 106, 110, 117, 141
 - human 109
 - intra-erythrocytic 95
 - virulent 107
 - parasites lyse 15
 - parasite species 9
 - patients 95, 100
 - pigment 167, 174
 - prevalence 107
 - prevention 25
 - prosper 4
 - regions 16
 - resistance 107
 - statistics 107
 - treatment 165
 - transmission 5, 12, 93, 107
 - local 22
 - treatment 109, 111, 114, 115, 125
 - Venture 53, 59
 - Malariaology Laboratory 169
 - Malarone 116
 - Marketed antimalarial formulations 107
 - Mebendazole 49
 - Mefloquine 20, 25, 26, 48, 49, 109, 119
 - Mercapto-jS 160, 161, 163
 - Merozoites 93, 164, 174
 - Metacyclic trypomastigotes 68, 69, 71
 - Metal complexes 156, 161, 163, 168, 174
 - Metallodrugs 169
 - Metals, transition 156, 157, 174
 - Metal treatments 156
 - Methylene blue 48, 49, 95
 - Metronidazole 46, 49
 - Mexicana 122, 123, 163, 164
 - Migrants 21, 26
 - Miltefosine 25, 57
 - Modifications, chemical 116
 - Molecular parasitology 51
 - Montevideo 168, 169
 - Movement of parasites worldwide 21
 - Multidrug-resistant 129, 130, 131, 135, 136, 137, 138, 139
 - Mutations 92, 101
- N**
- Nanoformulation 170, 171
 - Natural products 47, 48, 53, 54, 82, 83, 106, 107, 108, 109, 110, 140
 - N. caninum* 170, 171, 172
 - NCBI Pubchem 96, 97, 99
 - Neglected 5, 42, 52, 59
 - diseases initiative 52, 59
 - tropical diseases (NTDs) 5, 42, 59
 - Nervous 74, 75
 - fibers 74, 75
 - systems, autonomous 74, 75
 - Newborn babies 14
 - New drugs 52, 53, 77, 102
 - developing 77, 102
 - development of 52, 53
 - NGBS Consortium 53, 54
 - Nifurtimox 45, 46, 56, 58, 66, 77, 83, 162, 169
 - Nitazoxanide 46
 - Nitric oxide production 74, 170
 - Non-endemic countries 22, 67
 - Novartis institute for tropical diseases (NITD) 53, 59
 - N. pobeguinii* 120, 122

O

Omeprazole 49
Opportunistic infections 20, 27
Organ transplantation 66, 67
Oxorhenium 161, 163

P

Pantoprazole 49
Parasitaemia 107, 119
Parasite 8, 9, 16, 18, 24, 31, 51, 55, 69, 72, 73, 74, 81, 94, 101, 109, 110, 125, 113, 116, 119, 122, 139, 141, 158, 161, 162, 167, 169, 170, 171
autophagy, increased 162
biology 51
biology tutorial 94
burden 24
clearance 119, 170
complete 125
rapid 101
cysteine proteases 161
cytochrome bc1 55
development 113, 116
dispersion 9
entry site 72
growth 109, 110
identification 72
infections 18, 158, 171
interaction 69
invasion 69
load 170
membrane 171
Parasitemia 16, 31, 55, 74, 81, 113, 119, 122, 139, 141, 167, 169
high 16
low 73, 170
scanty 73

Parasite 8, 17, 46, 67, 74, 101, 107, 171
DNA 17
multiplication 171
replication 74
reservoir of infection 8
resistance 107
starves 46
susceptibility 101
transmission 67

Parasites 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 43, 44, 45, 46, 48, 50, 51, 55, 56, 66, 67, 68, 69, 70, 71, 72, 73, 75, 76, 81, 83, 92, 93, 94, 95, 97, 101, 107, 109, 110, 113, 116, 119, 126, 141, 156, 158, 159, 162, 163, 164, 165, 167, 170, 171, 173, 174
apicomplexan 11, 158, 170, 174
cultivated 110
eurixenous 11
intracellular 170, 173
monoxenous 9
opportunistic 20
polixenous 9
protozoal 30
resistant 165
stage 174
treatment-resistant 165
Parasitic 45, 52, 53, 59
drug development 52, 53, 59
membrane glutathione S-transferase 45
Parasitological diagnosis 76
Parasitophorous vacuole 170, 174
Parasitoses 41, 42, 43, 45, 46, 47, 50, 53
chronic 41
Pathogens 44, 45, 84, 157
cause disease 84
transmit disease 84
Perpetuate 14, 30

- P. falciparum* 5, 8, 13, 16, 22, 25, 45, 53, 55, 95, 97, 100, 109, 113, 115, 116, 117, 120, 122, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 138, 139, 141, 164, 166, 167, 168, 169
infections 22, 25, 166
malaria 109, 113, 116, 117
parasitaemia 122
strain 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139
strains 168
Phenoxyphenoxyethyl thiocyanate 51
Piperlonguminine 81
Piperovatine 81
Place Chagas' disease 67
Plant-derived 106, 108, 141
 compounds 108, 141
 drugs 106
Plasmodium falciparum 48, 50, 52, 78, 92, 93, 101, 106, 107, 141, 165, 168
 chloroquine-resistance transporter 101
 malaria 141
Plasmodium malariae 93
Plasmodium 101, 102, 126, 168, 174
 parasites 168
 strains 101, 102, 126
Plasmodium vivax 48, 92, 93, 95, 141
Pneumocystis 45, 46
Post-transfusion malaria 15, 16
 risk 16
Post-transplanted patients 19
Post-transplant 18
 malaria 18
 complication 18
 malaria complications, developed 18
Praziquantel 46, 57
Prevention of Chagas disease 24
Primaquine 55, 99, 100, 102, 109
Processes of parasite dispersion 9
Program 53, 96, 97, 99
 computer 96, 97, 99
 malaria drug discovery 53
Prohylaxis 3
Protein kinase C (PKC) 70
Proton pump inhibitors (PPIs) 49, 59
Protozoa, primogenital 3, 4
Protozoal diseases by transfusion 27
Protozoan parasites 4, 10, 141, 156, 158
 studding 4
Protozoan parasites infect 157
Protozoans 21, 92, 141, 157, 159
Pyrimethamine 102, 167
- Q**
- Quinacrine 48, 49
Quinine 46, 47, 48, 49, 92, 94, 95, 96, 102, 106, 107, 108, 109, 113, 114, 115, 125, 140, 141, 163, 165, 166
 discovery of 106, 108
 natural product antimalarial drugs 108
Quinolines 48, 49, 109, 113, 115, 119
- R**
- Reactive oxygen species 46, 170, 171
Reduced parasitemia 162, 168
 complex 168
Regimens, standard antimalarial 122
Reversed pharmacology 106, 112
Rodent malarial parasite 168
- S**
- Schizogony 170, 174
 replications 170

- Screening, high-throughput 51, 54
Selection, resistant parasite 100
Selenium 169
Serological tests 76
Seropositivity 17, 28, 31
Sesquiterpene lactones 47, 54, 78, 79, 98, 124, 125
Smeathxanthone 137
Society, poverty disease cost 30
Sodium stibogluconate 25, 46, 47, 57
Spiroindolones 54
Sporozoite parasite stage 174
Strains 25, 48, 57, 79, 80, 96, 97, 98, 101, 102, 127, 128, 129, 131, 132, 134, 162, 168, 169
 chloroquine-resistant 96, 98, 102, 168
 chloroquine-sensitive 97, 98
 resistant 48, 57, 101, 102, 131, 132, 134, 169
Strictosamide 120, 122
Strongyloidiasis 45, 46
Structure-activity relationships (SAR) 51, 59, 117, 123, 125, 142
Studied chemical composition 78, 79, 80, 81, 82
Study of seroprevalence 28
Subfamily Triatominae 70
Sulfate, uncomplicated malaria quinine 95
Surface glycoproteins 69
Symphonia globulifera 138, 139
- T**
- Tachyzoites 170, 171, 174
Tafenoquine 55
Tapeworm 43, 45, 46
T. brucei 56, 160
T. cruzi 23, 26, 75, 76, 80, 161
 epimastigotes 80, 161
 infection 23, 75, 76
 vectors 26, 70
Tetracycline 95, 96, 115
Therapy 5, 98, 102
 artemisinin-based combination 5, 98
 effective malaria 102
Tissue 74, 170, 173
 cysts 170, 173
 parasitism 74
Toxic drugs 95, 96
Toxoplasma 9, 18, 19, 30, 156, 159, 170, 171
Toxoplasma gondii 4, 9, 13, 20, 23, 28, 30, 156, 158, 170, 171, 172, 173, 174
Toxoplasmosis 3, 5, 6, 8, 23, 27, 28, 157
Transfusional malaria 15
Transmission 5, 13, 14, 27, 66, 67, 71, 72, 93
 congenital 13, 14, 27
 high malarial 5
 interrupting vector 71, 72
 malarian 93
 vertical 66, 67
Transmission 44, 66, 67, 164
 modes 66, 67
 vectors 44, 164
Transplanted organs 18, 19
Triatomines 68
 parasite-infected 68
Trichomonas vaginalis parasite 172
Trichomoniasis 3, 8, 9, 23, 46, 157, 158
Trypanosoma 156, 168
Trypanosoma cruzi 4, 10, 13, 18, 50, 66, 67, 68, 69, 71, 83, 161, 162
 protozoan parasite 67, 83
Trypanosomiasis 45, 46, 47, 157, 160, 168

Subject Index

Antiprotozoal Drug Discovery: A Challenge that Remains 189

- Trypomastigotes 68, 72, 75, 78, 80, 81,
82, 83, 162
strain 81, 82
Tulahuen strain epimastigotes 79
- V**
- Vanadium 156, 164, 174
Variant, virulent malaria
163 Vectors insects 67,
68
Vectors species 66, 67
- Vernodalin 124, 125
Vernonia amygdalina 124
Visceral leishmaniasis 7, 13, 14, 17, 19,
22, 24, 25, 27, 31, 42, 47, 53, 57, 162
congenital 14
Visceral leishmaniasis cases 7, 27